This article was aimed to study the therapeutic material basis of Xiong-Shao (XS) decoction on hepatic fi-brosis (HF), and screen effective parts from XS decoction for protecting liver, reducing enzyme activity and oxidative damage. Male wistar rats were randomly divided into the normal group, model group, Fu-Zheng Hua-Y u (FZHY) group, XS group, polysaccharide group, total alkaloids group and the total glycosides group. HF rat model was estab-lished with the intraperitoneal injection of DMN. After modeling, FZHY solution (0.105 g·mL-1), XS decoction (1.610 g·mL-1), crude polysaccharides extract of XS decoction (35.420 mg·mL-1), total glycosides extract solution (25.725 mg·mL-1), and total alkaloids extract of XS decoction (0.196 mg·mL-1) were administered to corresponding treatment group by gavage once a day for 4 weeks, respectively. Rats of the normal group and model group were given equiva-lent normal saline by gavage once a day for 4 weeks. After 4-week drug administration, rats were killed to remove the liver. Automatic biochemical analyzer was used in the detection of serum parameters of liver function, including ALT, AST, TIBL and ALB. Serum SOD activity was detected by xanthine oxidase. GSH-PX activity was tested by DTNB reduction. Serum contents of MDA were measured by TBA. Pathological changes of the liver were observed with HE staining and masson staining. The results showed that compared with the model group, there was no signifi-cant differences between the total alkaloids group and the model group, but levels of serum ALT, AST and TBIL of other treatment groups were significantly decreased, and the serum ALB level was significantly elevated (P< 0.05 or P < 0.01). Compared with the model group, levels of serum SOD and GSH-PX of the FZHY group, XS group and total alkaloids group were significantly elevated (P < 0.01), and level of serum MDA was significantly reduced (P <0.05 or P< 0.01). Comparison among the polysaccharides group, total glycosides group, and model group showed no significant differences. It was concluded that crude polysaccharide and total glycosides fractions were effective parts of XS decoction for protecting liver and reducing enzyme activity. And total alkaloids fraction was the effective part for reducing oxidative damage.

This study was aimed to study the therapeutic material basis of Xiong-Shao decoction (XSD) on hepatic fi-brosis (HF), and to screen the effective parts from XSD for regulating TGF-β/Smad pathway. Male Wistar rats were randomly divided into the normal group, the model group, the Fu-Zheng Hua-Y u (FZHY) capsule group, the XSD group, the crude polysaccharide group, the total glycosides group, and the total alkaloids group. Rats of the modeling group were intraperitoneally injected with dimethylnitrosamine (DMN) to establish HF model. After modeling, FZHY capsule solution (0.105 g·mL-1), XSD crude polysaccharides extract solution (35.420 mg·mL-1), XSD total glycosides extract solution (25.725 mg·mL-1), and XSD total alkaloids extract solution (0.196 mg·mL-1) were administered to the corresponding treatment group by gavage once a day for 4 weeks, respectively. Rats of the normal group and the model group were given equivalent amount of normal saline by gavage once a day for 4 weeks. The treatment course was 4 weeks. The expression of TGF-β1 mRNA of the liver tissues was detected by FQ-PCR. And the protein ex-pressions of Smad3 and Smad7 were detected by western blotting analysis. The results showed that compared with the model group, there was no significant difference in the expression of Smad7 protein between the total glyco-sides group and the model group, as well as no significant difference between the total alkaloids group and the model group. Expressions of TGF-β1 mRNA and Smad3 protein of other treatment groups were significantly re-duced. And the expressions of their Smad7 protein were significantly increased (P < 0.05 or P < 0.01). It was concluded that crude polysaccharide an d total glycosides fractions were the effective parts of XSD for regulating TGF-β/Smad pathway.

This study was aimed to observe the protective effect of extract from Rhizoma A nemones Raddeanae (RAR) on hepatic fibrosis induced by porcine serum in rats. A total of 68 SD rats were randomly divided into 5 groups, which were the normal group, model group, RAR group, extraction of RAR (EXRAR) group, Fu-Zheng Hua-Y u(FZHY) group. Each rat was intraperitoneally injected with 0.5~0.6 ml of porcine serum twice a week for 15 suc-cessive weeks to establish liver fibrosis model. Intragastric administration was given after the model was successfully established. The FZHY group was given FZHY capsule (0.525 g·kg-1). The RAR group was given RAR decoction (0.7 g·kg-1). The EXRAR group was given EXRAR (0.071 g·kg-1). The model group and normal group were given e-qual amount of physiological saline. The medication was given once a day. And the treatment course was 8 weeks. At the end of the 23th week, rats were sacrificed. Contents of SOD and MDA in blood serum were assayed. The protein expressions of α-SMA and TGF-β1 in liver tissues were detected by SABC. The results showed that compared with the model group, content of MDA decreased in the EXRAR group, RAR group and FZHY group (P<0.05), and content of SOD increased obviously (P<0.05). In the model group, expression of α-SMA and TGF-β1 increased, with dark brown dyeing and diffusion area. Expression area and strength of the FZHY group, RAR group, and EXRAR group were ob-viously weak with tasteless interval dyeing and no formation of typical pseudolobule in comparison with the model group. The color rendering index showed that compared with the model group, the protein expression of α-SMA and TGF-β1 decreased obviously in liver tissues of the FZHY group, EXRAR group, and RAR group (P< 0.05). It was concluded that RAR and its extract had a good antifibrosis effect. And the EXRAR had basically the same antifibrosis effect as RAR. It was assumed that the possible mechanism was related with the inhibiting of hepatic stellate cell (HSC) activation and the expression of TGF-β1 as well as the resisting of lipid peroxidation.

Objective To analyze the treatment and medication rules of formulae containing prepared rehmannia root in Pharmaceutical Standard of Ministry of Public Health of the People's Republic of China-Traditional Chinese Patent Medicine (referred to as Traditional Chinese Patent Medicine). Methods Through Traditional Chinese Medicine Inheritance Support Platform (V2.5), prescriptions containing prepared rehmannia root in traditional Chinese patent medicine were selected and collected to build the database. Frequency counts,association rules and other data mining methods were used to analyze the frequency of indication syndromes and medicine combination of prescription containing prepared rehmannia root, and the compatibility rule of high frequency drug pairs and the rescription rule of core syndromes were analyzed. Results There were a total of 467 prescriptions containing pepared rehmannia root, involving 28 combinations of commonly used Chinese herbals (support degree 30%). The compatibility source of high-frequency drug pairs of prepared rehmannia root and Angelicae Sinensis, prepared rehmannia root and Astragalus embranaceus were both of Shiquan-Dabu decoction in Taiping Huimin Heji Ju Fang (support degree 40%). There were a total of 81 indication syndromes, and among them, there were 16 kinds of high-frequency indication syndromes (the frequency greater than or equal to 10). The core drug combination of high-frequency indication syndromes of "deficiency of both qi and blood" (137 times) and "deficiency of kidney yang" (63 times) were the subtract of Shiquan-Dabu decoction and Yougui pill in Jingyue Quanshu respectively. Conclusions Prepared rehmannia root is mainly compatible with herbs of nourishing blood, supplementing qi and invigorating yang in the traditional Chinese patent medicine containing prepared rehmannia root. The traditional Chinese patent medicine containing prepared rehmannia root were based mainly on classical prescriptions. This study can provide reference for clinical application and new drug development of pepared rehmannia root.

OBJECTIVE:To provide reference for clinical application and related new drug R&D of the couplet medicines of Platycodon grandiflorum-Glycyrrhiza uralensis. METHODS:All set prescription preparations containing P. grandiflorum-G. uralensis in Ministry of Public Health Drug Standard·TCM Set Prescription Preparation were collected;data mining and analysis for the syndrome and treatment rules of these prescriptions were performed by using TCM Inheritance System V 2.5. RESULTS:There were a total of 315 set prescription preparations containing couplet medicine of P. grandiflorum-G. uralensis , 89 main syndromes and 88 main diseases. Among of them,high frequency major syndrome were exterior syndrome attacked by wind-heat and exterior syndrome tightened by wind-cold,and dominating medicine combination were respectively Yinqiao powder and Xingsu powder. High frequency main diseases were common cold and cough. Core medicine combination in the treatment of common cold included Yinqiao powder, Xingsu powder,Huoxiang zhengqi powder and Chaihu zhijie decoction,etc. Core medicine combination in the treatment of cough included Xingsu powder,Zhisou powder,Tongxuan lifei pills and Qingjin huatan decoction,etc. CONCLUSIONS:The study confirms the syndrome and treatment rules of set prescription preparations containing couplet medicines of P. grandiflorum-G. uralensis , and could provide evidence for clinical application of the couplet medicines of P. grandiflorum-G. uralensis and new drug R&D.

OBJECTIVE： To investigate the changes of extraction rates of forsythiaside A and forsythin in Forsythia suspensa compatible with other medicinal material of Menshi huwei formula before and after decoction. METHODS： HPLC method was used to determine the extraction amounts and to calculate the extraction rates of forsythiaside A and forsythin in F. suspensa （5 g×7 doses）， F. suspensa （5 g×7 doses） compatible with Pinelliae rhizoma praeparatum cum zingibere et alumine （PRZA）， Menshi huwei formula [including 6 ingredients as F. suspense （5 g×7 doses）， PRZA] after decocted with water. The determination was performed on Diamonsil C18 column with mobile phase consisted of acetonitrile-0.2％ formic acid solution （gradient elution）. The detection wavelength was set at 278 nm， and the column temperature was 30 ℃. The flow rate was 1.0 mL/min. RESULTS： The linear range of forsythiaside A and forsythin were 0.61-6.1， 0.246-2.46 μg （r＝0.999 7， 0.999 9）， respectively； RSDs of precision， stability （within 20 h） and reproducibility tests were all lower than 2％ （n＝6）. Average recovery rates were 96.10％-99.37％ （RSD≤2.36％，n＝6） respectively. In F. suspensa， extraction rates of forsythiaside A and forsythin were 96.90％ and 66.67％. In F. suspensa compatible with PRZA， extraction rates of them were 101.61％ and 54.55％. In Menshi huwei formula， extraction rates of them were 98.39％ and 84.85％. CONCLUSIONS： After F. suspensa is compatible with PRZA， the extraction rates of forsythiaside A is increased while forsythin is decreased. After compatible with other medicinal material in Menshi huwei formula， extraction rates of both are increased slightly.